Werner Baumann, Bayer CEO (Malte Ossowski/SVEN SIMON/picture-alliance/dpa/AP Images)
Bayer's next-gen drug Nubeqa aces survival test in metastatic prostate cancer, putting it in competition with giants
In the battle for market dominance in prostate cancer, Bayer’s Nubeqa has made a late entry into the field but holds high hopes for eventual …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
